Novartis: positive trial results in acute heart failure

(CercleFinance.com) - In-hospital initiation of Novartis' Entresto provided superior benefit compared to commonly used heart failure medicine enalapril for stabilising heart failure patients, the Swiss drugmaker said on Monday.


According to results presented at the American Heart Association's Scientific Sessions and published in The New England Journal of Medicine, Entresto showed a significant 46% reduction in the risk of a composite of death, heart failure re-hospitalization, or listing for cardiac transplantation, compared to enalapril, over 8 weeks.

Patients with heart failure who need to be admitted to the hospital due to decompensation of their disease are at high short-term risk of death or risk of being re-admitted to the hospital, Novartis said.

Copyright (c) 2018 CercleFinance.com. All rights reserved.